Skip to content

Novo teams up with Evotec in kidney diseases

August 18, 2020

Novo Nordisk (NYSE:NVO) will collaborate with Evotec SE (OTCPK:EVOTF) on the discovery and development of novel therapies for the treatment of chronic kidney disease (CKD).

The companies will jointly identify and develop new targets based on comprehensive medical and molecular datasets of thousands of CKD patients. They will share responsibilities during drug discovery and preclinical development while Novo will be responsible for clinical development and commercialization.

Novo will pay Evotec an upfront fee, research funding, up to €150M in milestones per product and tiered royalties on net sales. Additional financial terms remain confidential.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: